The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s demonstrating significant potential in clinical trials for treating obesity. Unlike some available weight loss treatments, retatrutide appears to offer a greater substantial loss i